Fintel on MSN9h
Cantor Fitzgerald Initiates Coverage of Acrivon Therapeutics (ACRV) with Overweight Recommendation
Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...
decrypt15h
Stablecoin Giant Tether Reports Record Profits Ahead of Bitcoin Rollout
Alongside record profits, USDT issuer Tether also reported Friday it now holds over $143 billion in reserve assets to back ...
Trump Says Looming Oil Tariffs Are Negotiable: ‘Depends On What Their Price Is’
All else equal, this would increase gasoline prices, which in most of the country have averaged $3 per gallon for the past ...
Cantor Fitzgerald Sticks to Its Buy Rating for Cipher Mining (CIFR)
In a report released yesterday, Brett Knoblauch from Cantor Fitzgerald maintained a Buy rating on Cipher Mining (CIFR – Research Report), with ...
Intel (INTC) Receives a Hold from Cantor Fitzgerald
Cantor Fitzgerald analyst C J Muse maintained a Hold rating on Intel (INTC – Research Report) yesterday and set a price target of $22.00. The ...
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform
Cantor Fitzgerald analysts initiated coverage of Acrivon Therapeutics Inc (NASDAQ:ACRV) with an Overweight rating. The initiation comes with a positive outlook on the company's potential in the ...